Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22455362 | 1.00 | TSHR (0.42) | TSHRACHETP53TDP1POLB | |
| SCHEMBL19249177 | 0.90 | ACHE (0.36) | TSHRACHETP53TDP1POLB | |
| SCHEMBL19398886 | 0.90 | ACHE (0.38) | TSHRACHETP53TDP1POLB | |
| SCHEMBL30908179 | 0.85 | ACHE (0.38) | TSHRACHETP53TDP1POLB | |
| SCHEMBL9342999 | 0.80 | TSHR (0.41) | TSHRACHETP53TDP1POLB | |
| SCHEMBL11793622 | 0.78 | ACHE (0.39) | TSHRACHETP53TDP1POLB | |
| SCHEMBL10201143 | 0.78 | TSHR (0.50) | TSHRTP53TDP1POLBGAA | |
| SCHEMBL23774976 | 0.76 | TSHR (0.41) | TSHRACHETP53TDP1POLB | |
| SCHEMBL2580862 | 0.76 | TSHR (0.41) | TSHRACHETP53TDP1POLB | |
| SCHEMBL6527556 | 0.76 | TSHR (0.41) | TSHRACHETP53TDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4641695-A1 | ELECTROCHEMICAL APPARATUS AND ELECTRONIC DEVICE | Dongguan Amperex Technology Limited (CN) | 2025-10-29 | — | — | EP | claimed |
| EP-3941459-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12539295-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2025-10-30 | — | — | US | disclosed |
| EP-4641695-A1 | ELECTROCHEMICAL APPARATUS AND ELECTRONIC DEVICE | Dongguan Amperex Technology Limited (CN) | 2025-10-29 | — | — | EP | disclosed |
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| WO-2024233604-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-11-14 | — | — | WO | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4501701-A | 20-Isocyano-Δ17(20) -steroids | ROUSSEL UCLAF (FR) | 1985-02-26 | — | — | US | disclosed |
| US-4456561-A | CYCLOHEXYL-, CYCLOHEXENYL-, AND CYCLOHEXENYL- IDENE NITRILES | POLAK'S FRUTAL WORKS, B.V. (NL) | 1984-06-26 | — | — | US | disclosed |
| US-4401596-A | Novel 17-oxazoline-steroids | ROUSSEL UCLAF (FR) | 1983-08-30 | — | — | US | disclosed |
| US-4388237-A | NEUROLEPTIC, SEDATIVE, HYPNOTIC, ANALGESIC, ANTIDEPRESSANT | BASF AKTIENGESELLSCHAFT (DE) | 1983-06-14 | — | — | US | disclosed |
| US-4336204-A | Menthene nitriles and use as perfume chemicals | POLAK'S FRUTAL WORKS, B.V. (NL) | 1982-06-22 | — | — | US | disclosed |
| US-4336192-A | ANALGESICS, SEDATIVES, ANTICHOLINERGIC AGENTS, ANTIEMETICS | BASF AKTIENGESELLSCHAFT (DE) | 1982-06-22 | — | — | US | disclosed |
| EP-0019157-A1 | 5,6-Dihydro-11-alkylene-morphanthridin-6-ones and process for their preparation | BASF Aktiengesellschaft (DE) | 1980-11-26 | — | — | EP | disclosed |
| US-4235805-A | MENTHANE CARBON SKELETON | POLAK'S FRUTAL WORKS B.V. (NL) | 1980-11-25 | — | — | US | disclosed |
| US-4219449-A | Carane nitriles | POLAK'S FRUTAL WORKS B.V. (NL) | 1980-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | TSHR 629/4885ACHE 4619/4885TP53 2236/4885 |
| US-12539295-B2 | IRAK degraders and uses thereof | IRAK2, IRAK4, IRAK3 | TSHR 357/4885ACHE 4164/4885TP53 3635/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | TSHR 334/4885ACHE 4219/4885TP53 3456/4885 |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, IRF3 | TSHR 4788/4885ACHE 3610/4885TP53 246/4885 |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | TSHR 4177/4885ACHE 1071/4885TP53 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.